Congressional Republicans Want to Know if 340B Plays a Role in Drug Shortages

Drug shortages
The GOP leaders of two congressional committees want public input on whether 340B program growth leads to drug shortages.

U.S. House Energy & Commerce Committee Chair Cathy McMorris Rodgers (R-Wash.) and Senate Finance Committee ranking Republican Mike Crapo (Idaho) are soliciting public input on what’s driving the increase in drug shortages, including whether or not the 340B drug pricing

Read More »

First Merck, Now Chamber of Commerce Sues to Stop Medicare Drug Price Negotiation

U.S. Chamber of Commerce
The U.S. Chamber of Commerce and local and state chambers have sued to stop Medicare from negotiating "maximum fair prices" on a small number of expensive single-source drugs.

The U.S. Chamber of Commerce and three state and local affiliates are asking a federal court to strike down the part of the Inflation Reduction Act that lets Medicare negotiate “maximum fair prices” (MFPs) for some expensive, single-source drugs, arguing

Read More »

Federal Court Hearing Next Week on California’s Medicaid Drug Benefit Transfer; Bill Introduced in N.J. with 340B Implications

U.S. District Court Sacramento
A federal district judge in Sacramento, Calif., is holding arguments next week in a lawsuit to reverse the state’s transfer of Medicaid managed care benefits to Medicaid fee for service.

A federal district judge in Sacramento, Calif., is holding oral arguments next week in a lawsuit aimed at reversing the state’s January 2022 transfer of Medicaid managed care benefits to Medicaid fee for service.

Meanwhile, a bill was introduced

Read More »

Protest Held at Indiana Congressman’s State Office Against His 340B Hospital Reporting Bill

AHF Bucshon
AIDS Healthcare Foundation advocates marched yesterday outside U.S. Rep. Larry Bucshon's (R-Ind.) Terre Haute, Ind., office to protest Bucshon's bill to impose reporting requirements on 340B hospitals and potentially other covered entities.

AIDS Healthcare Foundation staged a march yesterday outside U.S. Rep. Larry Bucshon’s (R-Ind.) Terre Haute office to protest his bill that would require 340B disproportionate share hospitals to report data about patients who get 340B drugs, spending on charity care,

Read More »

Merck Sues to Stop Medicare Drug Price Negotiation

Merck
Merck has sued to stop the federal government from negotiating prices for certain high expenditure, single source Medicare Part B or Part D drugs

Federal Medicare drug price negotiation “is tantamount to extortion” and must be struck down as unconstitutional, drug manufacturer Merck told a federal district court yesterday.

Merck on Tuesday became the first drug maker to sue to stop the federal government

Read More »

CMS Creates New Group to Lead Medicaid Managed Care Policy

CMS
CMS has created a new group within the CMS Center for Medicaid and CHIP Services to develop and manage federal Medicaid managed care policy.

The U.S. Centers for Medicare & Medicaid Services (CMS) said this week it has created a new unit within the CMS Center for Medicaid and CHIP Services (CMCS) to develop and manage federal Medicaid managed care policy.

CMS announced the

Read More »

HHS, HRSA Tell Judge They Don’t Know When They’ll Replace 340B Dispute Resolution Process

340B administrative dispute resolution
HHS and HRSA recently told a federal district court they “are unable to predict” when they will finally replace HRSA’s 340B administrative dispute resolution proces.

The U.S. Department of Health and Human Services and the Health Resources and Services Administration “are unable to predict” when they will finally replace HRSA’s 340B administrative dispute resolution process, the government said in a recent legal filing.

The government

Read More »

HRSA Posts Four Manufacturer Notices to 340B Entities

Humalog
Lilly is providing refunds for 340B overcharges during Q1 2020 on Humalog and Trulicity.

The U.S. Health Resources and Services Administration yesterday posted notices of refunds for 340B overcharges from drug manufacturers Lilly, Novo Nordisk, and Neurocrine and a notice from Amneal about product NDC changes.

Lilly

Lilly’s May 30 notice covers purchases

Read More »

HRSA Allows Immediate 340B Enrollment in Guam Due to Typhoon

Guam typhoon Mawar
Destruction in Tamuning, Guam, caused by super typhoon Mawar, which made landfall on May 24 as a Category 4-equivalent storm.

Health care providers in Guam eligible to participate in the 340B program may do so immediately, rather than having to wait for the next normal quarterly registration period July 1-15, the U.S. Health Resources and Services Administration said yesterday.

Secretary

Read More »

Merck to Pay Refunds for 340B Overcharges in Q1 and Q2 2020

Cubicin
Merck is providing refunds for 340B overcharges on NDCs of its antibiotic Cubicin and other drugs during the first two quarters of 2020.

Drug manufacturer Merck is paying refunds for overcharges on 340B drugs purchased during the first two quarters of 2020.

Merck recently asked the U.S. Health Resources and Services Administration to post notices about its 340B ceiling price recalculations on the

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live